Core Scientific, Inc. cash flow to debt ratio of 26.24% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Core Scientific, Inc.'s free cash flow has decreased 765.74% from $-52.06M last year to $-450.75M, signaling decreasing performance

Core Scientific, Inc.'s debt to equity ratio is -1.78, signaling that the company spent its equity and risk bankruptcy.

Core Scientific, Inc.'s debt to equity ratio is -1.78, signaling that the company spent its equity and risk bankruptcy.

Core Scientific, Inc. has negative EBITDA, making leverage ratio unreliable

Core Scientific, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Core Scientific, Inc.'s profit margin has decreased (26.56%) in the last year from -257.50% to -325.91%, signaling decreasing performance

Core Scientific, Inc.'s short-term assets of $895.54M exceed its short-term liabilities of $781.40M

Core Scientific, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Core Scientific, Inc.'s return on equity of 98.70%, is higher than 15.00%, indicating good performance

Core Scientific, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Core Scientific, Inc. has insufficient public price history to evaluate earnings stability.

Core Scientific, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Core Scientific, Inc. has negative free cash flow, indicating cash burn

Core Scientific, Inc.'s yearly earnings has increased -78.05% since last year from $-1.32B to $-288.62M, signaling increasing performance

Core Scientific, Inc.'s yearly revenue has decreased 37.53% since last year from $510.67M to $319.02M, signaling decreasing performance

ROIC -5.89% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Core Scientific, Inc.'s 3-year revenue CAGR of -20.72% is negative, indicating declining revenue over the past 3 years

Core Scientific, Inc. has insufficient public price history to evaluate revenue consistency.

Core Scientific, Inc. has insufficient public price history to evaluate ROE consistency.

Core Scientific, Inc. has insufficient data to evaluate this check.

Core Scientific, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Core Scientific, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Core Scientific, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Core Scientific, Inc. has insufficient data to evaluate this check.

Core Scientific, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Core Scientific, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Core Scientific, Inc. has a price-to-sales ratio of 14.36x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue